Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949101 | 0.95 | GPR119 (0.56) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL7692137 | 0.94 | GPR119 (0.58) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL7420864 | 0.94 | GPR119 (0.58) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL11980483 | 0.93 | GPR119 (0.48) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL561360 | 0.90 | HPGD (0.53) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL15085741 | 0.90 | GPR119 (0.59) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL8151168 | 0.86 | GPR119 (0.55) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL560636 | 0.86 | GPR119 (0.55) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL5039032 | 0.85 | GPR119 (0.47) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL8206 | 0.85 | HPGD (0.54) | GPR119FAAHHPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108787-A | FAPI modified by 4- (p-iodophenyl) butyric acid, nuclide marker, preparation method and application | 核工业四一六医院 | 2024-05-31 | — | — | CN | claimed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025137500-A1 | KINASE INHIBITION AND DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025101571-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X L DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5618843-A | INHIBIT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0635492-A1 | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | GPR119 2666/4885FAAH 1738/4885HPGD 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.